Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Chong Wei, Wei Zhang, Dao-Bin Zhou, Jian Li, Yan Zhang, Kaini Shen, Wei Wang, Zi Wang, Danqing Zhao, Jing Ruan, Huacong Cai, Yueying Mao

Blood (2025) 146 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2025-6322

Published: 2025

Journal Articles

Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associated disorders

Danqing Zhao, Huishan Sun, Jian Li, Hanping Wang, Yan Zhang

Blood (2025) 146 (Supplement 1): 189.

https://doi.org/10.1182/blood-2025-189

Published: 2025

Journal Articles

Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study

Yan Zhang, Huiying Zhu, Zhangyuting He, Danqing Zhao, Chong Wei, Jing Ruan, Jian Li, Wei Zhang, Dao-Bin Zhou

Blood (2025) 146 (Supplement 1): 5471.

https://doi.org/10.1182/blood-2025-5471

Published: 2025

Journal Articles

Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China

Huiying Zhu, Zhangyuting He, Chong Wei, Jing Ruan, Danqing Zhao, Wei Zhang, Jian Li, Dao-Bin Zhou, Yan Zhang

Blood (2025) 146 (Supplement 1): 3693.

https://doi.org/10.1182/blood-2025-3693

Published: 2025

Journal Articles

The Clinical Characteristics and Prognostic Analysis of Prolonged Cytopenia after CAR-T Cell Therapy

Huiying Zhu, Danqing Zhao, Zhe Zhuang, Chao Chen, Wei Zhang, Daobin Zhou, Jian Li, Yan Zhang

Blood (2024) 144 (Supplement 1): 7148.

https://doi.org/10.1182/blood-2024-207024

Published: 2024

Journal Articles

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Chao Chen, Jingjing Yin, Wei Wang, Danqing Zhao, Chong Wei, Cong-Wei Jia, Wei Zhang, Jian Li, Daobin Zhou, Yan Zhang

Blood (2024) 144 (Supplement 1): 6395.

https://doi.org/10.1182/blood-2024-202966

Published: 2024

Journal Articles

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Siyuan Li, Yuhan Gao, Yue Dang, Long Chang, Kaini Shen, Huacong Cai, Danqing Zhao, Chong Wei, Jun Feng, Lu Zhang, Jian Li

Blood (2024) 144 (Supplement 1): 6292.

https://doi.org/10.1182/blood-2024-203586

Published: 2024

Journal Articles

Multicenter Real-World Use of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma(DLBCL) of Frontline and Relapse/Refractory Settings in China

Zhangyuting He, Huiying Zhu, Chong Wei, Danqing Zhao, Wei Wang, Jian Li, Wei Zhang, Daobin Zhou, Yan Zhang

Blood (2024) 144 (Supplement 1): 6504.

https://doi.org/10.1182/blood-2024-203008

Published: 2024

Journal Articles

Development of a New Risk Scoring System Based on Spleen Involvement and the Lymphocyte/Monocyte Ratio for Follicular Lymphoma Patients

Chunyuan Li, Wei Zhang, Danqing Zhao, Ping Yang, Wei Wan, Shuozi Liu, Hongmei Jing

Blood (2022) 140 (Supplement 1): 11990.

https://doi.org/10.1182/blood-2022-164665

Published: 2022

Journal Articles

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Yan Zhang, Wei Wang, Jian Li, Daobin Zhou, Wei Zhang, Danqing Zhao, Chong Wei, Lu Zhang, Xinxin Cao

Blood (2022) 140 (Supplement 1): 6608–6609.

https://doi.org/10.1182/blood-2022-165934

Published: 2022

Journal Articles

Preliminary Results of Zanubrutinib-Containing Regimens in DLBCL and Cerebrospinal Fluid Distribution of Zanubrutinib

Yan Zhang, Yanan Li, Zhe Zhuang, Wei Wang, Chong Wei, Danqing Zhao, Jian Li, Daobin Zhou

Blood (2021) 138 (Supplement 1): 4556.

https://doi.org/10.1182/blood-2021-150949

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Golidocitinib combined with CHOP in newly-diagnosed peripheral T-cell lymphoma: Preliminary Results from A phase 1/2 clinical trial

Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associated disorders

Chemotherapy-free induction with pomalidomide, orelabrutinib, and rituximab (POR) followed by high-dose methotrexate,rituximab and orelabrutinin (ROM) in newly diagnosed primary CNS lymphoma: Interim analysis of a phase II study

Exploration of optimal high-dose methotrexate-based therapy for patients with primary CNS lymphoma: A real-world study in China

The Clinical Characteristics and Prognostic Analysis of Prolonged Cytopenia after CAR-T Cell Therapy

CHOP Is Insufficient for Newly-Diagnosed Subcutaneous Panniculitis-like T-Cell Lymphoma Patients: A Retrospective Study of 32 Patients in China

Real-World Data of Siltuximab for Chinese Patients with Imcd: Combination with BCD Regimen Benefits Severe Cases

Multicenter Real-World Use of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma(DLBCL) of Frontline and Relapse/Refractory Settings in China

Development of a New Risk Scoring System Based on Spleen Involvement and the Lymphocyte/Monocyte Ratio for Follicular Lymphoma Patients

Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Preliminary Results of Zanubrutinib-Containing Regimens in DLBCL and Cerebrospinal Fluid Distribution of Zanubrutinib

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only